

CITATION REPORT

List of articles citing

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

DOI: 10.3389/fphar.2020.01329

Frontiers in Pharmacology, 2020, 11, 01329.

Source: <https://exaly.com/paper-pdf/76024785/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 185-192	5.9	4
10	Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta [®] in Healthy Chinese Male Volunteers. <i>Frontiers in Pharmacology</i> , 2021 , 12, 660541	5.6	0
9	Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 821944	5.6	0
8	The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva [®]) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.. <i>International Immunopharmacology</i> , 2022 , 107, 108666	5.8	2
7	A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
6	A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.		0
5	Editorial: Women in drug metabolism and transport: 2021. 13,		
4	Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study. 1-8		0
3	Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study. 2023 , 38, 117-125		0
2	Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial. 2023 , 37, 259-269		0
1	Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial. 1-11		0